<p><strong>Patients with hepatic impairment</strong>: In patients with severe hepatic impairment, Armodafinil should be administered at a reduced dose.<br />
<br />
<strong>Patients with renal impairment</strong>:There is inadequate information to determine safety and efficacy of dosing in patients with severe renal impairment.</p>